KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Gains from Sales and Divestitures (2019 - 2022)

Pacific Biosciences Of California has reported Gains from Sales and Divestitures over the past 4 years, most recently at $2.6 million for Q4 2022.

  • For Q4 2022, Gains from Sales and Divestitures rose 43.6% year-over-year to $2.6 million; the TTM value through Dec 2022 reached $2.6 million, up 43.6%, while the annual FY2022 figure was $2.6 million, 43.6% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2022 was $2.6 million at Pacific Biosciences Of California, up from $2.4 million in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $2.6 million in Q4 2022 and troughed at $2026.0 in Q2 2022.
  • A 4-year average of $1.0 million and a median of $876000.0 in 2020 define the central range for Gains from Sales and Divestitures.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 989.74% in 2020 and later crashed 99.86% in 2022.
  • Year by year, Gains from Sales and Divestitures stood at $204000.0 in 2019, then soared by 390.2% to $1.0 million in 2020, then soared by 79.8% to $1.8 million in 2021, then surged by 43.6% to $2.6 million in 2022.
  • Business Quant data shows Gains from Sales and Divestitures for PACB at $2.6 million in Q4 2022, $2.4 million in Q3 2022, and $2026.0 in Q2 2022.